Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16133 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y203-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2020-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7ed210288e30d612547eb54a33ed77c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_268525b37401fa37e2dcf93172cc4f4f |
publicationDate |
2020-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020297839-A1 |
titleOfInvention |
FcRn-TARGETED THERAPEUTICS FOR THE TREATMENT OF ANTIBODY-MEDIATED AUTOIMMUNE AND ALBUMIN-MEDIATED DISEASE |
abstract |
The present disclosure is drawn to HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein. The disclosure provides a method of treating auto-immune mediated and albumin-mediated diseases in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising HCMV US11 (herein after referred to as “US11”) polypeptide, polypeptide fragments, or variants thereof. The disclosure also provides methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection. |
priorityDate |
2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |